Roundup settlement agreements face legal scrutiny as a Missouri judge approved a $7.25 billion payout over two decades to resolve cancer claims against agrochemical maker Bayer.
St. Louis Circuit Judge Timothy Boyer issued the written judgment on Friday, granting approval to the nationwide class-action settlement. The decision addresses thousands of claims from U.S. cancer patients who asserted that the company failed to warn users that the popular weed killer could cause non-Hodgkin lymphoma, AP News reported.
Individual payouts will vary based on product exposure, age at diagnosis, and illness severity. Participants could receive an average between $10,000 and $165,000, according to AP News. Agricultural, industrial, and turf workers exposed to the herbicide at length who were diagnosed with an aggressive form of the disease while younger than age 60 could receive an average of $165,000. Claimants diagnosed at age 78 or older will receive significantly less, averaging $10,000.
Boyer described the total dollar amount as “among the largest in the history of mass tort personal-injury class action settlements.” The approved package includes $600 million designated for attorneys’ fees.
Legal Division Over Payout Fairness
Attorneys representing cancer patients expressed sharply contrasting views regarding the fairness of the financial terms. Christopher A. Seeger, a court-appointed counsel for cancer patients, praised the final approval order.
“[Today’s final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice,” said Christopher A. Seeger, a court-appointed counsel for cancer patients in the case.]
Other lawyers argued the individual compensation amounts are inadequate and lock in future claimants for decades without the possibility of punitive damages.
“This settlement is the scariest, worst future settlement that’s ever been contemplated,” said attorney Gerson Smoger during a September court hearing on whether the settlement was fair. Smoger asserted that the agreement left the product on the market, allowing victims to face continued exposure.
Boyer rejected objections from opposing attorneys, stating that further delays could leave seriously ill and terminal patients waiting an indeterminate number of years for compensation, DW.com reported. The judge also noted a risk that Bayer could have sought bankruptcy protection had the settlement been rejected.
Corporate Strategy and Supreme Court Impact
For Germany-based Bayer, which maintains that Roundup does not cause cancer, the resolution offers financial certainty amid mounting legal costs. Bayer CEO Bill Anderson called the court-approved settlement a decisive milestone in the company’s strategy to mitigate risks from pending and future litigation.
Bayer previously acquired Monsanto in 2018 for $63 billion, inheriting the legal battles surrounding the herbicide. Since the acquisition, Bayer shares have fallen 46%, and the company has faced roughly 200,000 total claims. The company previously agreed to a $10.9 billion settlement in 2020, but failed to secure court approval for a separate $1.25 billion agreement intended to cover future cases, according to The Guardian.
The settlement arrived five months after the U.S. Supreme Court ruled in June that Bayer cannot be sued in state courts on claims of failing to warn about cancer. The high court determined that federal regulations do not require a cancer warning label and forbid states from imposing additional labeling mandates. Agri-Pulse reported that the 7-2 ruling found the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-level failure-to-warn cases.
While Bayer denies that glyphosate causes cancer, the World Health Organization’s International Agency for Research on Cancer classified the chemical as “probably carcinogenic” in 2015. Conversely, the U.S. Environmental Protection Agency determined that glyphosate is not likely to cause cancer in humans when used as directed.
Frequently Asked Questions About the Settlement
Who is covered under the Missouri court approval?
The settlement applies to Roundup users who are currently ill and individuals diagnosed with non-Hodgkin lymphoma in future years, provided they were exposed to the product before the agreement was proposed in February.
How are attorneys compensated in this class action?
The approved settlement allocates $600 million specifically for attorneys’ fees out of the total $7.25 billion fund.
What is the status of ongoing litigation outside this class action?
Bayer said that approximately 200 federal court cases remain in active litigation, where the company plans to utilize defenses stemming from the recent Supreme Court ruling.
Lawyers for some of the Roundup victims who objected to the settlement did not immediately respond to requests for comment.
Worth a look